Clinical Trial Update: Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study [Phase 4]

View source ↗

Summary

A Phase 4, single-centre, open-label, single-arm trial evaluating Ropustin for refractory aplastic anemia after radiotherapy; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Ropustin

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Aplastic Anemia | Phase 4 | Status: NOT_YET_RECRUITING